MedTrace Logo

Differential EBI2 Expression Upon Allelic Status of the rs9557195 Polymorphism

NCT03633409 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 340

Last updated 2018-08-21

No results posted yet for this study

Summary

EBI2 is a risk gene for inflammatory bowel diseases (rs9557195). Patients of the Swiss IBD cohort study have been genotyped for the allelic status of EBI2. The investigators will test the influence of rs9557195 genoty (TT or CC allel), inflammatory activity and current treatment (infliximab vs. vedolizumab) on expression and activity of EBI2 on blood lymphocytes, mRNA expression of EBI2 and UBAC2 (located on the opposite DNA strand of EBI2) and activity of lymphocytes on a migraton assay.

Conditions

  • Inflammatory Bowel Diseases

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-01
Primary Completion
2018-12-01
Completion
2018-12-01

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633409 on ClinicalTrials.gov